Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage.


Journal

Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329

Informations de publication

Date de publication:
May 2023
Historique:
received: 08 12 2022
accepted: 08 03 2023
medline: 19 4 2023
pubmed: 25 3 2023
entrez: 24 3 2023
Statut: ppublish

Résumé

Tumor-associated macrophage (TAM)-derived IL-6 is involved in small-cell lung cancer (SCLC) progression and chemoresistance via the activation of signal transducer and activator of transcription 3 (STAT3) in the tumor microenvironment. This study aimed to identify natural compounds that suppress cell-cell interactions between TAMs and SCLC cells by inhibiting STAT3 activation. We used a library of natural compounds to identify candidate agents possessing anti-SCLC effects by inhibiting macrophage-induced tumor proliferation. SBC-3 and SBC-5, human SCLC cell lines, were used for in vitro experiments. Furthermore, we assessed the efficacy of these candidate agents in a murine xenograft model of human SCLC. Among the natural compounds examined, onionin A (ONA) inhibited IL-6-induced STAT3 activation and SCLC cell proliferation. ONA also reduced the secretion of IL-6 from macrophages and interfered with the direct effect of cell-cell interactions between macrophages and SCLC cells. Furthermore, ONA administration suppressed tumor progression in a tumor-bearing mouse model. ONA was identified as the most useful candidate for targeting cell-cell interactions between cancer cells and TAMs for anti-SCLC therapy.

Identifiants

pubmed: 36961655
doi: 10.1007/s13577-023-00895-6
pii: 10.1007/s13577-023-00895-6
pmc: PMC10110690
doi:

Substances chimiques

onionin A 0
Interleukin-6 0
STAT3 Transcription Factor 0
STAT3 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1068-1080

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 19K08603
Organisme : Japan Society for the Promotion of Science
ID : 22K08257
Organisme : Japan Society for the Promotion of Science
ID : 20H03459
Organisme : Japan Society for the Promotion of Science
ID : 16K09247
Organisme : Japan Society for the Promotion of Science
ID : 22K08284

Informations de copyright

© 2023. The Author(s).

Références

Cancers (Basel). 2014 Mar 26;6(2):708-22
pubmed: 24675568
PLoS One. 2012;7(2):e30820
pubmed: 22319590
Cancer Res. 2018 Jun 15;78(12):3255-3266
pubmed: 29610117
Oncol Rep. 2011 Dec;26(6):1533-7
pubmed: 21922144
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Thorac Oncol. 2016 Apr;11(4):453-74
pubmed: 26829312
J Nat Prod. 2010 Jul 23;73(7):1306-8
pubmed: 20597533
J Thorac Dis. 2017 Nov;9(11):4185-4186
pubmed: 29268466
Cancer Immunol Immunother. 2019 Mar;68(3):489-502
pubmed: 30637473
J Cancer Res Clin Oncol. 2009 May;135(5):723-30
pubmed: 19002495
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Cancer Sci. 2010 Oct;101(10):2128-36
pubmed: 20860602
Front Mol Neurosci. 2018 Apr 03;11:98
pubmed: 29666569
Pathol Int. 2016 Sep;66(9):491-505
pubmed: 27444136
Ther Adv Med Oncol. 2010 Sep;2(5):301-7
pubmed: 21789142
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Front Immunol. 2022 Jul 28;13:959495
pubmed: 35967372
Mol Diagn Ther. 2011 Dec 1;15(6):347-52
pubmed: 22208386
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Mol Ther Oncolytics. 2021 Feb 06;20:470-483
pubmed: 33718595
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
Ann Oncol. 2010 May;21 Suppl 5:v220-2
pubmed: 20555085
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
pubmed: 22700443
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
J Clin Exp Hematop. 2011;51(2):93-9
pubmed: 22104307
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Sci Rep. 2016 Jul 12;6:29588
pubmed: 27404320
Br J Cancer. 2009 Jun 16;100(12):1949-56
pubmed: 19455144
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Clin Exp Hematop. 2013;53(2):127-33
pubmed: 23995109
Lung Cancer. 2017 Apr;106:22-32
pubmed: 28285690
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Front Oncol. 2020 Dec 10;10:586580
pubmed: 33363016
Lung Cancer. 2009 Mar;63(3):315-21
pubmed: 18760859
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Aging (Albany NY). 2021 Oct 4;13(19):22883-22897
pubmed: 34607975
Cancer Sci. 2012 Dec;103(12):2165-72
pubmed: 22957741
Lung Cancer. 2013 Jun;80(3):256-62
pubmed: 23489559
Mol Nutr Food Res. 2016 Nov;60(11):2467-2480
pubmed: 27393711

Auteurs

Remi Mito (R)

Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Toyohisa Iriki (T)

Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Yukio Fujiwara (Y)

Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan. fuji-y@kumamoto-u.ac.jp.

Cheng Pan (C)

Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Tsuyoshi Ikeda (T)

Department of Natural Medicine, Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-Ku, Kumamoto, 860-0082, Japan.

Toshihiro Nohara (T)

Department of Natural Medicine, Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-Ku, Kumamoto, 860-0082, Japan.

Makoto Suzuki (M)

Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Takuro Sakagami (T)

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Yoshihiro Komohara (Y)

Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.
Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH